Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Volunteers

Exclusion Criteria

• •1. Clinical diagnosis or laboratory evidence of renal, hepatic, central nervous system, respiratory, cardiovascular, or metabolic disease at Screening.
• •2. Diagnosed with any form of malignancy (except basal cell carcinoma, fully removed).
• •3. Clinically significant immunodeficiency or autoimmunity assessed by medical history and/or laboratory test results.
• •4. Active or latent tuberculosis (TB), regardless of treatment history,
• •5. Positive drug abuse test.
• •6. Positive HIV, HBV, HCV test results.
• •7. Clinically significant ECG test results.
• •8. Clinically significant vital sign results.